Novartis receives three new FDA approvals for the expanded use of Ilaris
Novartis announced the FDA has granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. Ilaris is the first and only FDA approved biologic treatment for TRAPS, HIDS/MKD and FMF. September 23, 2016